Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lujia Zhou

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Nature Communications|May 12, 2017
Tau association with synaptic vesicles causes presynaptic dysfunctionLujia Zhou, Joseph McInnes, Keimpe Wierda, et al.
International Journal of Retina and Vitreous|February 2, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationJoseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsJoseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, et al.
EMBO Molecular Medicine|March 30, 2022
AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease modelMarika Marino, Lujia Zhou, Melvin Y Rincon, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Nature Communications|May 12, 2017
Tau association with synaptic vesicles causes presynaptic dysfunctionLujia Zhou, Joseph McInnes, Keimpe Wierda, et al.
International Journal of Retina and Vitreous|February 2, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationJoseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsJoseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, et al.
EMBO Molecular Medicine|March 30, 2022
AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease modelMarika Marino, Lujia Zhou, Melvin Y Rincon, et al.
Pageof 6